US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.32 against a street estimate of -0.19 — a miss of 68.4%.
Analysts rate Tilray Inc a buy (3 buy, 7 hold, 0 sell out of 10) with an average price target of $5.72.
MIXED Tilray delivered record revenue and gross profit, led by BrewDog and international cannabis, but EBITDA declined and the company remains loss-making with significant interest expense. Q1 FY27 Europe benefited from medical cannabis demand, Life in the UK, and BrewDog. Canada faced planned strain rotations and supply constraints, while U.S. beer showed brand-level momentum amid a challenging market. Analysts pressed management on BrewDog’s profitability, Canadian cannabis revenue declines, Carlsberg’s potential, M&A priorities, and German reimbursement changes. Management emphasized integration progress, temporary Canadian factors, strategic scale, and disciplined capital allocation. 2026-10-08…
Full summary in the app.
| Fund | Stake |
|---|---|
| 1 NORTH WEALTH SERVICES LLC | 0.00% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tilray Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.